Good health is vital to all of them , and finding sustainable solutions to the most pressing health care challenges of their world cannot wait. That's why they at Pfizer are committed to applying science and their global resources to improve health and well-being at every stage of life. They strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them. They have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Research Grants 410 show all


$97.7M
2015

$18.2M
2016

$112.5M
2017

$135.6M
2018

$160.8M
2019

Publications 17,892 show all

  • 258
    Drug Design
  • 210
    Pharmaceutical Preparations/metabolism
  • 199
    Models, Biological
  • 182
    Enzyme Inhibitors/pharmacology
  • 180
    Pharmaceutical Preparations/chemistry
  • 150
    Arthritis, Rheumatoid/drug therapy
  • 141
    Anti-Bacterial Agents/pharmacology
  • 127
    Neoplasms/drug therapy
  • 126
    Antineoplastic Agents/therapeutic use
  • 121
    Drug Discovery/methods

Patents 119,192show all

  • 23,755
    C07D - Heterocyclic compounds
  • 12,297
    A61K - Preparations for medical, dental, or toilet purposes
  • 8,853
    C07C - Acyclic or carbocyclic compounds
  • 3,198
    C07K - Peptides
  • 3,120
    A01N - Preservation of bodies of humans or animals or plants or parts thereof
  • 2,668
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 1,993
    C12N - Microorganisms or enzymes
  • 1,728
    C08G - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
  • 1,728
    C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients
  • 1,726
    C07H - Sugars

Clinical Trials 6,550show all

1,507Phase 31,345N/A1,114Phase 21,060Phase 1655Phase 4267Other

SEC Filings show all


254
8-K

78
10-Q

24
10-K

Contact Information

235 East 42nd Street
New York, NY 10017
United States

Overview

Total FundingEmployeesLast Funding DateStatus
10000+Ipo